Hite Christopher sold 3,927 shares of Royalty Pharma plc at $58.93 for −$231k on Sep 22, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
EVP & Chairman, Partnering
EVP & Chairman, Partnering
Filed Sep 24, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$231,402.79Shares × reported price
Shares traded
3,927Class A Ordinary Shares
Price per share
$58.93Reported price. Read footnotes for ranges.
% of reported position traded
1.43%This security and ownership context
Holdings after
270,401Indirect · By SCH Investment Partners LLC
Trade date
Sep 22, 2026Sell
Filed
Sep 24, 2026, 4:10 PM ET2-day reporting delay
Accession
0001814238-26-000017Code S · Transaction 228928
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 274,328 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 22, 2026Sell96,073$58.51−$5,621,692.38Trade 228927
2 transaction rows in this filing. Joint filers share the same rows.

RPRX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
RPRX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +5.2%1w ago +0.3%1d ago +1.1%
Returns since7d −1.1%30d +9.6%90d180d1y

Footnotes in full

F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.88 to $58.87 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.88 to $59.00 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.